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Human bocavirus (HBoV) is a widespread respiratory 
virus. To improve diagnostic methods, we conducted im-
munoglobulin (Ig) G and IgM enzyme immunoassays with 
recombinant virus–like particles of HBoV as antigen. Acute-
phase  and  follow-up  serum  samples  from 258  wheezing 
children and single serum samples from 115 healthy adults 
in Finland were examined. Our assays had a sensitivity of 
97% and a specificity of 99.5%. Of adults, 96% had immu-
nity; none had an acute infection. Of 48 children with sero-
logically diagnosed acute HBoV infections, 45 were viremic 
and 35 had virus in nasopharyngeal aspirates (NPAs). Of 
39 HBoV NPA PCR–positive children co-infected with an-
other virus, 64% had a serologically verified HBoV infection. 
HBoV caused illness of longer duration than rhinovirus and 
of equal severity to that of respiratory syncytial virus. Among 
children  with  bronchiolitis,  >25%  had  acute  HBoV  infec-
tions. Accurate HBoV diagnosis requires serologic analysis 
or PCR of serum; PCR of NPAs alone is insufficient.
A 
new parvovirus, human bocavirus (HBoV), was dis-
covered during sequencing of respiratory tract sam-
ples from children. It has been detected worldwide in the 
nasopharyngeal tract, mainly in small children with lower 
respiratory tract infections (1,2). HBoV has been associated 
with upper and lower respiratory tract infections and shown 
to be a cause of pneumonia in children (3–8). Prolonged 
shedding of virus has been reported; >26% of children shed 
virus for 2 months, 4% for 3 months, and 2% for 4 months 
(9).  Diagnosis  of  HBoV  respiratory  tract  infections  has 
been PCR based, leading to overrepresentation of HBoV 
co-infections with other respiratory viruses (9–11).
Along with others, we have shown that respiratory in-
fections with HBoV elicit B-cell immune responses (11–
15) and can be diagnosed serologically by using prokary-
otic virus protein 2 (VP2) antigens in immunoblots (11). 
We report production in insect cells of VP2 of virus-like 
particles (VLPs) and their use in enzyme immunoassays 
(EIAs)  for  detection  of  HBoV-specific  immunoglobulin 
(Ig) M and IgG in paired serum samples of pediatric patients 
with acute wheezing and in single serum samples of young 
healthy adults. Serologic results were compared with those 
of HBoV quantitative PCR (qPCR) of nasopharyngeal as-
pirates (NPAs) and paired serum samples of 258 children 
with complete sample sets. Clinical signs and symptoms of 
wheezing children with serologically verified acute HBoV 
infections with or without other respiratory virus infections 
(15 other viruses studied [10]) were compared with those 
of children infected with respiratory syncytial virus (RSV) 
or rhinovirus.
Materials and Methods
Patients and Samples
Acute-phase (at the time of admission) and convales-
cent-phase (2 weeks later) serum samples and NPA samples 
at the time of admission were obtained from 259 children 
(age range 3 months to 15 years, median 1.6 years) with 
acute expiratory wheezing (10,16). These children were 
tested by NPA PCR for 16 respiratory viruses (10); 117 of 
these children were tested by HBoV IgM and IgG immuno-
blots and HBoV serum qPCR (10,11). All remaining serum 
samples, except 1 convalescent-phase serum sample that 
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was depleted, were tested by HBoV qPCR specific for the 
nucleoprotein 1 gene as described (11); all serum samples 
were tested by EIA. For 93 of these 258 children, follow-up 
serum samples were obtained 5–8 years later. In addition, 
115 serum samples from healthy medical students were 
collected after informed consent was obtained. The study 
was reviewed and approved by the Ethics Committees of 
Turku and Helsinki University hospitals.
Expression of VP2
The putative major virus capsid protein VP2 gene (nt 
3443–5071) of the HBoV St 2 isolate (GenBank acces-
sion no. DQ000496) was cloned into a baculovirus vector 
pAcSG2 (Becton Dickinson Biosciences, Franklin Lakes, 
NJ, USA) by standard procedures and confirmed by se-
quencing. The VP2-containing vector was transfected into 
Sf9 insect cells by using FuGENE 6 Transfection reagent 
(Roche, Basel, Switzerland). Two million adherent cells 
in T25 bottles were transfected in 1 mL of Insect Express 
media (Lonza, Basel, Switzerland) with a mixture of 2 
µg  plasmid,  250  ng  linearized  baculoGold  DNA  (Bec-
ton Dickinson Biosciences), and 15 µL FuGENE reagent. 
Fresh cells were infected 3 times every third day by using 
virus medium collected from the previous infection. VP2-
containing Sf9 cells were harvested on day 3, and cell pel-
lets were resuspended in phosphate-buffered saline (PBS), 
pH 7.5, at a concentration of 2.1 × 107 cells/mL. Protease 
inhibitor (complete EDTA-free; Roche) was added (≈75 
µL/mL), and cells were lysed by sonication (4 × 20 s). 
After subsequent centrifugation at 13,200 rpm for 3 min, 
VLPs were purified by 48-h CsCl gradient ultracentrifuga-
tion at 24,200 rpm (L-70 Ultracentrifuge; Beckman, Ful-
lerton, CA, USA) at 4°C after fraction collection and dialy-
sis against PBS. The product was concentrated in columns 
(Amicon  Ultra-15  50,000  MWCO;  Millipore,  Billerica, 
MA, USA). Expressed HBoV VP2 was confirmed by so-
dium dodecyl sulfate–polyacrylamide gel electrophoresis 
to have a molecular mass of ≈60 kDa and by electron mi-
croscopy to be spherical symmetric parvovirus-like parti-
cles ≈20 nm in diameter (Figure 1). Before use as antigen, 
VLPs were biotinylated as described (17) .
Serologic Analysis
The HBoV IgG EIA was conducted as described for 
parvovirus B19 (18) except that biotinylated VLPs were 
used at concentrations of 60 ng/well. Cutoff values were 
calculated from IgG EIA absorbances of the first serum 
sample obtained at admission of 34 children who had no 
IgM or maternal (waning) IgG against HBoV and showed 
a >4-fold increase of IgG against HBoV during follow-up 
testing. Cutoff absorbances for negative and positive IgG 
EIA results were 0.154 (mean + 3 SD) and 0.188 (mean + 
4 SD), respectively.
For IgM EIA, a µ-capture format was used (19). Serum 
samples diluted 1:200 in PBS and 0.05% Tween (PBST) 
were applied in duplicate into wells of plates coated with 
goat  anti-human  IgM  (Cappel/ICN  Biomedicals,  Costa 
Mesa, CA, USA) for 60 min at room temperature. After 
being rinsed 5 times with PBST, biotinylated HBoV VLPs 
were applied at a concentration of 25 ng/well and incu-
bated for 45 min at 37°C. Bound antigen was visualized 
by  using  horseradish  peroxidase–conjugated  streptavidin 
(Dako, Glostrup, Denmark) at 1:12,000 in PBST plus 0.5% 
bovine serum albumin for 45 min at 37°C, followed by o-
phenylenediamine dihydrochloride (Dako) and H2O2 for 15 
min at 37°C. Cutoff values were calculated from IgM EIA 
absorbances of 5-year follow-up samples of 61 children 
who were IgG positive 5 years earlier. Cutoff absorbances 
for negative and positive IgM EIA results were 0.136 (mean 
+ 3 SD) and 0.167 (mean + 4 SD), respectively. Parvovirus 
B19 serologic analysis was conducted by using commercial 
(Biotrin, Dublin, Ireland) and in-house EIAs (18,20).
Statistical Analysis
Because most continuous data were skewed (by Kolm-
ogorov-Smirnov test), they were analyzed by using regres-
sion analysis and generalized linear models after logarith-
mic transformation. Logistic regression analysis was used 
for categoric data. Statistical analyses were conducted by 
using SAS/STAT(r) software version 9.1.3 SP4 (SAS In-
stitute Inc., Cary, NC, USA).
Results
qPCR
Complete sets of HBoV qPCR results for NPAs and 
serum  samples  were  available  for  258  children  (Table 
1). Among these children, 49 (19%) showed viremia in 
the first serum sample (29/49 [59%]), the second sample 
(12/49 [24%]), or both samples (8/49 [16%]). Most chil-
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Figure 1. Recombinant human bocavirus virus protein 2 virus-like 
particles. Scale bar = 100 nm. Bocavirus-induced Wheezing in Children
dren who showed viremia in the first sample (62%) or both 
samples (87%) had a high (>104 copies/mL) HBoV-DNA 
load in NPAs; most children who showed viremia only in 
the second sample (58%) had DNA-negative NPAs. These 
findings suggest a very recent infection. HBoV DNA loads 
in serum samples ranged from 112 copies/mL to 600,000 
copies/mL and did not correlate with NPA DNA loads. 
Forty-nine (19%) of 258 children had NPAs that were PCR 
positive, but  only  34  (13%)  had  both  NPAs  and  serum 
samples that were PCR positive; 194 (75%) children had 
negative PCR results for both sample types (Table 1). Of 
long-term follow-up serum samples, only 1/93 was PCR 
positive; this sample was from a child who was seronega-
tive 5 years earlier and seroconverted during follow-up. All 
115 adult serum samples were HBoV PCR negative.
Antibody EIAs
Of 258 wheezing children, 111 (43%) had serologic evi-
dence of past infection; 48 (19%) of acute primary HBoV in-
fection (Table 1; Figure 2). Of the latter group, 32 had detect-
able IgM with either IgG conversion (27/48) or a diagnostic 
increase (5/48); a total of 15 had IgM with no IgG (5/48) 
or with a constant IgG (10/48) absorbance value. A girl 1 
year of age showed seroconversion in a convalescent-phase 
serum sample weakly positive for IgG but she had no IgM 
in either sample (Table 1). All other children who showed 
seroconversion or an increase in IgG were IgM positive. In-
cidence rates of serologically verified, acute, primary HBoV 
infection among wheezing children varied with age, with a 
peak of 28% in children 1–<2 years of age (Table 2). Preva-
lence of HBoV immunity increased with age, reaching 100% 
at 7 years of age (Table 2). This study included 27 (10%) of 
258 children <6 months of age (median 4.8 months, mean 
4.7 months). Eight (30%) of 27 children were IgG positive; 
IgG in 7 of these children was presumably of maternal ori-
gin. One infant (3.7%), a 3.6-month-old boy, had a serologi-
cally verified acute HBoV infection.
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Table 1. Human bocavirus EIA and quantitative PCR results for 258 wheezing children, Finland* 
Serodiagnoses, IgM+,† no (%)  No serodiagnoses, no. (%) 
PCR result  No. children  SDG  SC  SI  IgG+  IgG– All  IgG+  IgG– Maternal 
NPA+ serum+  34 33 (97)  21 4 6 2 1 0 1 0
NPA+ serum–  15 2 (13)  0 0 2 0 13 10 3 0
NPA– serum–  194 1† (0.5)  1† 0 0 0 193 100 88 5
NPA– serum+  15 12 (80)  6 1 2 3 3 1 2 0
NPA+ 49 35 (71) 21 4 8 2 14 10 4 0
NPA+, high load  28 27 (96)  21 3 2 1 1 0 1 0
NPA+, low load  21 8 (38)  0 1 6 1 13 10 3 0
Serum+ 49 45 (92)  27 5 8 5 4 1 3 0
NPA– 209 13 (6) 7† 1 2 3 196 101 90 5
Serum– 209 3 (1.4) 1† 0 2 0 206 110 91 5
Any PCR+  64 47 (73)  27 5 10 5 17 11 6 0
Total 258‡ 48 (19)  28 5 10 5 210 111 94 5
*EIA, enzyme immunoassay; Ig, immunoglobulin; serodiagnoses (SDG), IgM positive and/or IgG conversion or increase; no serodiagnoses, IgM negative 
and no seroconversion/increase; SC, seroconversion; SI, serologic increase (>-fold increase in IgG); IgG+, constant level (<4-fold increase) of IgG in 
paired serum samples; IgG–, IgG negative in both serum samples; NPA, nasopharyngeal aspirate; Serum+, PCR positive in either or both serum 
samples. 
†One child was IgM negative. The IgG value of the convalescent-phase serum sample barely exceeded the cutoff value and the child was considered as 
not having an acute human bocavirus infection. 
‡One of 259 children (10) was not included in this comparison because of depletion of the convalescent-phase serum sample before the PCR (NPA and 
acute-phase serum samples were PCR negative; both serum samples were IgG positive and IgM negative, indicating immunity). 
Figure  2.  Scatter  plots  of  individual  absorbance  values  at  492 
nm (A492) of immunoglobulin (Ig) G (×) and IgM (red dots) against 
human  bocavirus  (HBoV)  in  enzyme  immunoassays  (EIAs)  for 
acute-phase  (I),  convalescence-phase  (II),  and  5-year  follow-
up (III) serum samples from wheezing children and single serum 
samples from young healthy adults, Finland. The 45 children with 
confirmed acute HBoV infections (by viremia and serodiagnosis) 
were divided into 3 groups according to the degree of acuteness 
(very acute, acute, and subacute) on the basis of findings in I and 
II serum samples. Very acute, I sample seronegative but II sample 
IgM positive (n = 12); acute, I sample IgM positive but IgG showed 
seroconversion (n = 20); subacute, IgG positive with a diagnostic 
increase or constant level in I and II samples, IgM positive (n = 13). 
Also shown are results for children without viremia or serodiagnosis 
(nonacute [for only the first 45 children with seropositive samples]), 
and young healthy adults (n = 115). EIA cutoffs are indicated by 
a blue line (IgG; 0.188) or a red line (IgM; 0.167). Dots below the 
cutoff lines indicate samples with absorbance values less than the 
negative cutoff values (i.e., IgM  – and IgN  – results).RESEARCH
Comparison of qPCR and EIA results for 258 children 
is shown in Table 1. Among 49 children who showed vire-
mia, 45 (92%) had a serodiagnosis of HBoV infection: i.e., 
had IgM or an increase in IgG. Of the remaining 4 viremic 
children, 1 was seropositive and 3 were seronegative; 2 of 
the seronegative children showed viremia in a second sam-
ple, possibly indicating a very acute infection (their NPA 
samples at the time of admission had been PCR negative). 
Among 209 nonviremic children, 206 (99%) showed non-
diagnostic serologic results (Table 1). Only 3 (1.4%) of 209 
children had a serodiagnosis: the 1-year-old girl with an ap-
parent false seroconversion described above and 2 children 
with PCR-positive NPAs and a positive result for IgM but a 
constant IgG level, which suggests a subacute infection.
Of 49 (19%) of 258 HBoV NPA PCR-positive chil-
dren, 35 (71%) had a serodiagnosis, 33 of whom were also 
viremic (Table 1). Of 28 patients with a high load of HBoV 
DNA  in  NPAs,  27  (96%)  had  an  HBoV  serodiagnosis, 
compared with only 8 (38%) of 21 with a low DNA load. 
Conversely, among 209 children without HBoV DNA in 
NPAs, 13 (6%) had a serodiagnosis, of whom 12 were also 
viremic.
Among 34 (13%) of 258 children who were HBoV 
PCR positive by both NPAs and serum samples, 33 (97%) 
had a serodiagnosis; the remaining child (a girl 6 months 
of age) was seronegative and viremic only in the second 
sample, which indicated a very acute infection. In contrast, 
of 194 (75%) of 258 children who were HBoV PCR nega-
tive in both NPAs and serum, only 1 (0.5%) had a serodiag-
nosis (the IgM-negative 1-year-old girl). Conversely, of 48 
(19%) of 258 children who had a serologically diagnosed 
acute HBoV infection, 35 (73%) were PCR positive for 
NPAs, 45 (94%) were viremic, and 47 (98%) were PCR 
positive for NPAs or serum (Table 1). If one considers a 
positive PCR result for serum as the standard for diagnosis 
(n = 258), our EIA had a sensitivity of 92%, a specificity of 
99%, and a positive predictive value of 94%. If PCR posi-
tivity for NPAs and serum is the standard for diagnosis (n 
= 128), the sensitivity is 97%, the specificity is 99.5%, and 
the positive predictive value is 97%.
All 258 children had been tested for 16 respiratory 
viruses (10). Of 12 (4.6%) with a serologically diagnosed 
acute HBoV single infection, 12 were viremic and 10 (83%) 
were HBoV DNA positive in NPAs (all with high DNA 
loads). Among 39 HBoV NPA PCR-positive children co-
infected with 1 or 2 other respiratory viruses (rhinovirus, 
enterovirus, RSV, adenovirus, influenza A virus, or parain-
fluenza virus), 25 (64%) had a serologically diagnosed pri-
mary HBoV infection; 17 (94%) of 18 with a high HBoV 
DNA load and 8 (38%) of 21 with a low HBoV DNA load 
had primary infections. Among viremic children with sero-
logically confirmed acute HBoV infections, 33 (73%) of 45 
had co-infections compared with 12 (92%) of 13 children 
with HBoV DNA in NPAs but without serodiagnosis or 
viremia; this difference was not significant (p = 0.26).
Follow-up  serum  samples  obtained  5–8  years  later 
were available for 93 of 258 children. Of 41 IgG-negative 
children, 38 (93%) had seroconverted, and all 21 acutely 
infected and all initially IgG-positive children were still 
IgG positive and had no IgM or HBoV DNA. Of 115 young 
adults, none had IgM, 110 (96%) had IgG (including 2 with 
borderline  results),  and  none  were  viremic.  Absorbance 
values are shown in Figure 2.
Serodiagnostic findings for infection with parvovirus 
B19 (IgM positive or low epitope-type specificity index) 
(18,20) were not observed among children with a serodi-
agnosis of HBoV infection. Among other children, 3 were 
IgM positive for parvovirus B19, of whom 1 was seronega-
tive for HBoV and 2 were seropositive for HBoV.
Clinical Characteristics
The 258 children tested for 16 viruses were analyzed 
for clinical characteristics. Median age of 46 children with 
acute HBoV infection diagnosed by serologic analysis and 
PCR of serum was 1.3 years (range 0.3–6.1 years), median 
age of  91 of 258 nonexposed seronegative children was 
1.1 years (range 0.2–4.2 years), and median age of 110 of 
258 children with HBoV immunity was 2.8 years (range 
0.5–5.2 years) (p<0.0001).
Clinical data were compared among children infect-
ed only with HBoV (n = 12), rhinovirus (n = 56), RSV 
(n = 36), and HBoV and any other virus (n = 34) (Table 
3), HBoV and rhinovirus (n = 14), and HBoV and RSV 
(n = 7). Among single infections, RSV induced wheezing 
earliest in life (median 0.8 years), followed by HBoV (1.4 
years) and rhinovirus (2.1 years; p<0.0001). Age-adjusted 
comparison of single infections showed longer duration of 
hospitalization (p = 0.0069), longer duration of cough (p 
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Table 2. Incidence rates of serologically verified acute human bocavirus infections and prevalence rates of bocavirus immunity among 
258 wheezing children, Finland*  
Age group 
Characteristic <6 mo  6–<12 mo  1–<2 y  2–<3 y  3–<4 y  4–<7 y  7–<15 y  Total
Incidence 1/26 (4)  9/37 (24)  25/88 (28)  5/42 (12)  3/25 (12)  2/19 (10)  0/14 (0)  45/251 (18) 
Prevalence 1/21† (5)  5/37 (13)  28/88 (32)  30/42 (71)  16/25 (64)  16/19 (84)  14/14 (100)  110/246† (45) 
*Values are no. positive/no. tested (%). Discrepant results of enzyme immunoassay and PCR results from 7 children were not included (see Table 1 and 
text).  
†Five infants had maternal antibodies (defined as waning immunoglobulin G absorbance values in paired serum samples). Two other infants became 
seronegative and were considered virus negative. Bocavirus-induced Wheezing in Children
= 0.0012), and longer duration of cough before admission 
(p<0.0001) for patients with acute HBoV infections than 
for patients with rhinovirus infections. However, children 
infected with rhinovirus had a higher leukocyte count at 
the time of admission (p = 0.0002). When compared with 
patients infected with RSV, patients infected with HBoV 
showed longer duration of cough before admission (p = 
0.019). Differences in clinical variables were not observed 
for rhinovirus or RSV, whether in children with single in-
fections or those co-infected with HBoV. We found no dif-
ferences between children co-infected with HBoV and 1 or 
2 other viruses. Nonrespiratory symptoms, including diar-
rhea, were rare (Table 3).
Acute  HBoV  infection  was  found  in  children  with 
bronchiolitis. Among children <2 years of age, acute HBoV 
infection was detected in 26 (27%) of 95 children having 
their first wheezing episode and in 35 (25%) of 141 chil-
dren having their first or recurrent wheezing episode, ex-
cluding asthmatic children (defined as children considered 
for initiation of daily long-term control therapy according 
to the recent US guidelines for diagnosis and management 
of asthma [21]). Children with HBoV and RSV single in-
fections showed a similar overall severity of illness (me-
dian 7, range 4–10 on a scale of 0–12), whereas acute oti-
tis media (AOM) was more frequent among children with 
RSV single infections (p = 0.0005) (Table 3).
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Table 3. Clinical characteristics of pediatric patients with acute wheezing caused by HBoV, rhinovirus, RSV, or mixed virus infections*†
Between groups infected with 
Virus infection 
Single virus
(n = 104) 
Single + mixed 
(n = 46)‡ 
Factor 
HBoV
(n = 12) 
Mixed
(n = 34) 
Rhinovirus
(n = 56) 
RSV
(n = 36)  p value§ 
Adjusted
p value¶  p value§ 
Age, y  1.4  
(0.8–3.2) 
1.3
(0.3–6.1) 
2.2
(0.4–12.5) 
0.9
(0.3–4.5) 
<0.0001 – 0.57
Male, no. (%)  9 (75)  23 (68)  36 (64)  20 (56)  0.45 0.073 0.64
At admission 
Severity of illness, scale 0–12  7 (4–10)  7 (2–10)  6 (2–10)  7 (4–10)  0.057 0.15 0.43
% Oxygen  saturation  97 (88–99)  96 (91–99)  96 (88–100) 96 (89–99) 0.98 0.97 0.95
Temperature, °C  37.6  
(36.1–39.1) 
37.7
(36.2–39.5) 
37.4
(36.2–39.3)
37.9
(36.3–40.1)
0.0014 0.032 0.71
CRP, mg/L  7.50 (0–78)  10 (0–45)  18 (0–191)  8 (0–96)  0.25 0.81 0.48
Leukocyte count, × 10
9/L 8.50  
(6.3–11.9) 
11.1
(5.1–23.6) 
12.1
(5.6–20.8) 
9.4
(4.9–20.7) 
0.0003 <0.0001 0.029
Duration of hospitalization, h  30 (18–78)  27 (6–90)  18 (6–74)  38 (6–138) <0.0001  0.0066 0.12
Duration of cough, d  15 (4–66)  11 (2–38)  8 (1–36)  11 (4–22)  0.0022 0.020 0.062
Before admission  5 (1–60)  3 (1–28)  2 (0–19)  4 (1–14)  <0.0001 <0.0001 0.038
After hospitalization  6 (2–14)  5 (0–14)  6 (0–14)  4 (0–13)  0.40 0.42 0.36
Moderate–severe after 
hospitalization
1 (0–8)  1 (0–14)  2 (0–14)  0 (0–4)  0.019 0.0052 0.34
Duration of breathing difficulty, h  4 (1–9)  4 (1–11)  3 (0–36)  6 (1–14)  <0.0001 0.0047 0.48
Before admission  1 (0–7)  1 (0–7)  1 (0–19)  2 (0–6)  0.040 0.67 0.63
After hospitalization  0 (0–4)  1 (0–10)  0 (0–14)  3 (0–11)  0.028 0.071 0.40
Moderate–severe after 
hospitalization
0 (0–0)  0 (0–6)  0 (0–14)  0 (0–1)  0.39 0.49 0.13
Other symptoms, no. (%) patients 
Acute otitis media  4 (33)  16 (47) 16 (29)  26 (72)  0.0003 0.073 0.41
Nonrespiratory symptoms 
Diarrhea 1 (8)  4 (12)  2 (4)  7 (19)  0.072 0.21 0.74
Balance problems  0 1 (3)  2 (4)  2 (6)  0.92 0.53 0.45
Rash 0 0 2 (4) 0 1.00 1.00 –
Arthritis or arthralgia  0 0 0 0 – – –
*Mixed infections consisted of HBoV plus >1 virus. Values are median (range) except as indicated. HBoV, human bocavirus; RSV, respiratory syncytial 
virus; CRP, C-reactive protein.  
†Analysis by regression analysis using generalized linear models after logarithmic transformation for continuous data or by logistic regression analysis for 
categorical data. Significant intergroup differences were found when persons with HBoV infections were compared with those with other infections: age: 
HBoV vs. RSV, p = 0.036; leukocyte count: HBoV vs. rhinovirus, p = 0.0009 unadjusted and p = 0.0002 adjusted; duration of hospitalization: HBoV vs. 
rhinovirus, p = 0.0027 unadjusted and p = 0.0069 adjusted; duration of cough: HBoV vs. rhinovirus, p = 0.0009 unadjusted and p = 0.0012 adjusted; 
duration of cough before admission: HBoV vs. rhinovirus, p<0.0001 unadjusted and p<0.0001 adjusted and HBoV vs. RSV, p = 0.028 unadjusted and p = 
0.019 adjusted; acute otitis media: HBoV vs. RSV, p = 0.0005 unadjusted. 
‡A child with 1 PCR-positive nasopharygeal aspirate and a PCR-negative serum sample was classified as having a subacute HBoV infection. In Table 1, 
he was 1 of 3 nonviremic children with a serodiagnosis for HBoV infection. 
§Unadjusted. 
¶Adjusted for age. RESEARCH
Discussion
HBoV infections have been commonly diagnosed by 
PCR  of  respiratory  tract  samples.  Only  a  few  serologic 
studies have been reported; these studies have addressed 
mainly epidemiologic issues (11–15). However, Endo et al. 
documented seroconversions by immunofluorescent anal-
ysis in 4 HBoV PCR-positive patients (12), and Lindner 
et al. detected IgM against HBoV by EIA in 12 patients, 
10 of whom were viremic children (15). In a study of 117 
wheezing children, we showed by using immunoblotting 
and prokaryotically expressed HBoV VP2 capsid antigens 
that HBoV infections can be diagnosed serologically (11). 
We also showed that the unique region in VP1 is far less 
immunogenic than the major virus capsid protein VP2. We 
have now expressed HBoV VP2 VLPs in insect cells for 
use in IgM and IgG EIAs that are superior to immunoblots 
in diagnostic performance. We diagnosed acute primary 
HBoV infections in 48 (19%) of 258 children with expi-
ratory wheezing. Consistent with other reports, no cross-
reactivity between 2 human pathogenic parvoviruses (B19 
and HBoV), was detected (11–13,15). Prevalence rates of 
immunity increased with age from 5% in infants to >64% 
in children 2–4 years of age and continued to increase until 
a maximum of 100% was reached in children 7 years of 
age. Seroprevalence among young adults was 96%. Fur-
thermore, IgG levels of adults were as diverse as those of 
children (Figure 2). These results contrast sharply with our 
previous immunoblot results with denatured VP2 antigen 
(11), which showed decreased seropositivity among chil-
dren >2 years of age. This difference is likely caused by 
a time-related conformational dependence of the antibody, 
similar to immunity to B19 virus (18,20,22,23). In other 
HBoV seroprevalence studies, similar rates were reported 
(12,13,15), which validate the accuracy of our results.
HBoV infection has been shown (by PCR of NPA sam-
ples) to be most prevalent in children 6 months to 3 years of 
age; adults are less affected (8,24–30). Consistent with this 
finding, the incidence of serologically verified acute HBoV 
infections in our study was highest (28%) during the sec-
ond year of life; median age of children with acute HBoV 
infections was 1.3 years. Only 2 children were infected at 
>4 years of age; 1 of them was seronegative. Children <6 
months of age might be protected from infection by ma-
ternal antibodies. Rapidly decreasing seroprevalence rates 
from ≈90% in infants <3 months of age to ≈5% in infants 6 
months of age were reported (12,13). In our study, 26% of 
27 children <6 months of age (including 1 infant <3 months 
of age) had maternal antibodies, and only 1 child in this age 
group had an acute HBoV infection.
When  we  compared  serologic  results  with  those  of 
PCR, we found a profound difference between NPA PCR 
results and serum PCR results. Although results of serodi-
agnosis were identical to results of serum analysis by PCR, 
only 71% of NPA-positive children and 6% of NPA-nega-
tive children had an HBoV serodiagnosis. However, all but 
1 (96%) of the children with a high load of HBoV DNA 
in NPAs had a serodiagnosis, compared with only 38% 
of those with a low DNA load. This finding supports the 
view that a low HBoV DNA load is not evidence of acute 
primary  infection  (10,11,31,32).  Studies  of  consecutive 
NPA samples have shown that HBoV DNA can persist in 
the nasopharynx for several months (9,33). We also noted 
that 22% of children with HBoV DNA in their first serum 
sample continued to show viremia (with 2 logs less DNA) 
in the second serum sample obtained an average of 19 days 
later. That HBoV does not often persist in serum indicates 
that regardless of its magnitude, viremia is an excellent 
marker of acute HBoV infection.
The clinical role of codetection of HBoV and other vi-
ruses in NPAs has been questioned. It is not easy to deter-
mine whether such co-infections are sequential infections or 
simultaneous viral infections. Serologic analysis is a more 
precise approach for diagnosis of HBoV infections. When 
compared with PCR-positive results in serum and NPAs, 
diagnostic sensitivity and specificity of our antibody EIAs 
were  as  high  as  97%  and  99.5%,  respectively;  positive 
predictive value was 97%. We showed by using EIAs that 
among wheezing children, >60% of co-infections in chil-
dren with HBoV NPA PCR-positive results, particularly in 
children with a high HBoV DNA load, are acute primary 
HBoV infections and should be considered in the diagno-
sis of respiratory disease. No differences in occurrence of 
co-infections were observed in children with a serologically 
confirmed diagnosis of infection with HBoV compared with 
children positive for HBoV by only PCR of NPAs.
Several  groups  have  compared  clinical  features  of 
HBoV infections with those of other respiratory virus infec-
tions. In those studies, diagnoses of infection with HBoV 
were based only on PCR positivity of NPAs, which as we 
showed, is not an ideal marker for detection of acute HBoV 
infection. We assessed clinical findings of our patients with 
serologically verified acute HBoV infections. Comparison 
of HBoV-induced wheezing with that induced by rhinovirus 
is notable because rhinovirus is commonly associated with 
wheezing in older children and has been recognized as a risk 
factor for recurrent wheezing and asthma in young children 
(34–36). Also notable is a comparison of HBoV and RSV 
because RSV is the dominant cause of bronchiolitis in in-
fants (37,38). Our data showed that wheezing induced by 
RSV occurred at the youngest age (median 10 months), fol-
lowed by that induced by HBoV (17 months), and rhinovirus 
(25 months). Age-adjusted comparisons showed that HBoV-
infected children were hospitalized longer than rhinovirus-
infected children. Illnesses after HBoV infection lasted lon-
ger than illnesses after rhinovirus infection. However, we did 
not demonstrate that co-infection with HBoV would increase 
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illness duration or severity, as has been reported for rhinovi-
rus- and RSV-induced bronchiolitis (39).
Children  with  HBoV  co-infections  seemed  to  have 
more AOM (47%) than those with single HBoV infections 
(33%), but this difference could be explained by inclusion 
of 7 RSV-positive children in this group. The highest rate 
of AOM (72%) was in children with RSV-induced wheez-
ing. Alper et al. reported differences in frequencies of vari-
ous respiratory viruses associated with AOM (HBoV was 
not included), but statistical significance was not achieved 
(40). We found a difference in the frequency of AOM be-
tween children with RSV-induced wheezing and those with 
HBoV-induced wheezing.
Serologically confirmed primary HBoV infections de-
tected in 12 symptomatic children with no signs of other 
respiratory virus infections (by PCR, culture, antigen de-
tection, or serologic analysis) demonstrate that HBoV is 
a cause of acute wheezing in young children. Moreover, 
the fact that acute HBoV infection was detected in 27% of 
hospitalized children who were <2 years of age when they 
had their first episode of wheezing indicates that HBoV is a 
causative agent of bronchiolitis with clinical severity com-
parable with that of RSV. HBoV respiratory infections can 
be diagnosed with moderate accuracy by qPCR of NPAs. 
However, the most reliable methods for diagnosis of acute 
symptomatic HBoV infection are PCR of serum samples 
and serologic analysis for IgM and IgG.
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